Glucagon-like peptide 1 (GLP-1) (7-36) acid is a derivative of the hormone and GLP-1 receptor (GLP-1R) agonist GLP-1 (7-36) amide.1,2 It enhances insulin-induced phosphorylation of Akt in 3T3-L1 adipocytes when used at a concentration of 100 nM in the presence of a dipeptidyl peptidase 4 (DPP-4) inhibitor.2 GLP-1 (7-36) acid (150 ?g/kg) reduces plasma levels of total cholesterol, triglycerides, free fatty acids, LDL, insulin, and leptin, as well as adipose tissue weight, in a mouse model of obesity induced by a high-fat diet. It decreases blood glucose levels, food intake, and gastric emptying in non-obese and ob/ob mice when administered at a dose of 3 mg/kg.1
References:
[1]. Fang, X., Du, Z., Duan, C., et al.Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse modelLife Sci.270:118966(2021).
[2]. Zhang, F., Chen, Z., Wu, D., et al.Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese miceiScience24(12)103382(2021).
















